Opendata, web and dolomites

theEoE

A novel drug candidate for the treatment of Eosinophilic Esophagitis - an innovative solution for a significant unmet medical need

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 theEoE project word cloud

Explore the words cloud of the theEoE project. It provides you a very rough idea of what is the project "theEoE" about.

thanks    reduces    occurs    eosinophilic    cellular    injury    28    discovery    modulation    wellbeing    remodeling    eoe    company    technologies    theeoe    first    generating    inflammation    cells    causing    bioavailability    clinical    accumulate    foods    points    efficacy    europe2020    complications    elicited    ip    therapy    approved    persists    promotion    esophagitis    physicians    epithelial    cure    eosinophils    thelial    spending    persistent    proprietary    nausea    risk    pain    symptoms    platform    pathologies    fewer    revolutionary    polarity    fits    decision    tissue    indications    compounds    disease    healthier    diseases    time    swallowing    health    investing    thelitetm    possibly    modulating    difficulty    patients    local    allergens    topical    uncontrolled    necessarily    people    vomiting    perfectly    environmental    regurgitation    embryo    benefit    innovation    offers    treatment    toxicology    cell    patented    white    manufacturing    integrity    series    barriers    progression    fly    drug    blood    smarter    revenue    prioritized    sustainable    esophagus    inflammatory    candidate    lower    modifies    line    applies    payers   

Project "theEoE" data sheet

The following table provides information about the project.

Coordinator
THELIAL TECHNOLOGIES SA 

Organization address
address: PARQUE TECNOLOGICO DE CANTANHEDE, NUCLEO 4, LOTE 3
city: CANTANHEDE
postcode: 3060197
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website http://www.thelial.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THELIAL TECHNOLOGIES SA PT (CANTANHEDE) coordinator 50˙000.00

Map

 Project objective

Thelial Technologies, S.A. is a revenue generating drug discovery company that applies its unique, proprietary fly embryo-based technology to find new candidate compounds for the treatment of diseases that can be addressed by cell polarity modulation. By modulating cell polarity it is possible to specifically target a series of indications, where reduced integrity of epithelial cellular barriers is a key to pathologies. Using Thelial’s patented discovery platform theLiTETM the company has identified 28 candidate compounds, of which one – theEoE has been prioritized for further development based on toxicology, efficacy, bioavailability, IP and manufacturing decision points. theEoE will be the first approved product for treatment of Eosinophilic Esophagitis (EoE). EoE is an inflammatory disease of the esophagus elicited by foods and possibly environmental allergens. It occurs when a type of white blood cells, eosinophils, accumulate in the esophagus and persists, causing local injury and inflammation. Currently, there are no specific cure for the EoE, causing patients’ reduced wellbeing due to uncontrolled and persistent symptoms (e.g. high difficulty in swallowing, pain, nausea, regurgitation, and vomiting). Thelial offers a targeted topical treatment that reduces the clinical symptoms, modifies disease progression through tissue remodeling, and increases the duration of treatment response. These features will allow physicians, patients and payers to benefit from a revolutionary new treatment with fewer side-effects, and lower risk of health complications thanks to a better management of the disease over time. By promoting a first in line targeted therapy for EoE, Thelial’s innovation project perfectly fits the “Europe2020 challenges – for a healthier EU” 1) spending smarter but not necessarily more in sustainable health systems and 2) investing in people’s health, particularly through health-promotion programmes.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THEEOE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THEEOE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More